Company expects multiple regulatory, clinical, and data milestones over the next 12 months
ImmunityBio plans a 2026 sBLA submission for QUILT-2.005 trial in BCG-naïve NMIBC
Company says current cash and marketable securities position supports commercial and clinical priorities
Overview
U.S. biotechnology firm's Q2 net product revenue rose 92% yr/yr, marking eighth straight quarterly gain
Adjusted net loss for Q2 narrowed to $81.0 mln from $89.9 mln a year earlier
Revenue growth driven by continued adoption of ANKTIVA and expanded market access
Result Drivers
ANKTIVA adoption - Co said Q2 revenue growth was driven by continued adoption of ANKTIVA among U.S. urologists and strong market access
Commercial activities - Increased net trade sales of ANKTIVA attributed to ongoing commercial activities
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
IBRX•
